Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients

The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patient...

Full description

Saved in:
Bibliographic Details
Published inCancer control Vol. 29; p. 10732748221140201
Main Authors Ismail, Mohamed A., Sorio, Claudio, Al-Dewik, Nader
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.11.2022
Sage Publications Ltd
SAGE Publishing
Subjects
Chronic myeloid leukemia
Myeloid leukemia
Protein-tyrosine kinase
Protein-tyrosine-phosphatase
Therapeutic applications
Therapeutic targets
Tumor suppressor genes
Tumors
View
CML 2
leukemia
PTPRG 3
BCR::ABL1
Online AccessGet full text

Cover

More Information
Summary:The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patients due to TKIs, still over 25% of CML patients need to switch TKIs at least once during treatment timeline for many reasons. On the other hand, PTPRG behave as a tumor suppressor gene in different neoplasms and is strongly down-regulated in CML patients. We discussed briefly in series of articles the possible reasons of it is down regulation. Here, we discuss its role as potential therapeutic target in treatment plan.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1073-2748
1526-2359
DOI:10.1177/10732748221140201